Alok Kumer

Alok Kumer

Auto-generated profile, based on publicly available information

Alok Kumer

Computational and AI-Driven Drug Discovery Unit, OxUpp BioResearch Center, OxUpp Bangladesh

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
Sohel RanaSohel Rana
Sohel Rana
MHMd. Sanowar Hossan
Md. Sanowar Hossan
Abdullah Al RafiAbdullah Al Rafi
Abdullah Al Rafi
DHDeri Damien Hagidok
Deri Damien Hagidok
AKAlok Kumer
Alok Kumer
RARasel A. Al-Amin
Rasel A. Al-Amin
Protein arginine methyltransferase 5 (PRMT5) is a promising anticancer target, yet existing inhibitors shown limited clinical efficacy. Here, we paired multi-omics pan-cancer profiling with a machine learning virtual screening pipeline. Bioinformatics analyses with TIMER3, GEPIA2, UALCAN/CPTAC, the Human Protein Atlas, cBioPortal, STRING and Enrichr revealed widespread of PRMT5 mRNA expression, protein abundance, survival, genetic alteration, immune infiltration and co-expression networks with tumor-specific prognostic impact in GBM, LGG and KIRC. A deep neural network screened about 1.5 million PubChem compounds and deep neural network reached a ROC-AUC = 0.9857 and prioritized three candidates, CID 44345182, CID 2794188 and CID 44345334. Subsequent molecular docking against PRMT5 (PDB ID: 4X61), ADMET filtering and toxicity prediction, and 100 ns molecular dynamics (MD) simulations identified CID 44345182 as the potential hit, similar the docking scores of −9.8 compared with - 9.2 kcal/mol for the reference ligand in binding affinity and trajectory stability. These findings clarify the context-dependent roles of PRMT5 and further experiment validations are needed to establish CID 44345182 as a promising candidate.